Litcius/Paper detail

Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial

Jun Zhao, Liang Zhao, Wei Guo, Shuhang Wang, Xiuli Tao, Lin Li, Yousheng Mao, Fengwei Tan, Yushun Gao, Ning Wu, Jianming Ying, Qi Xue, Ning Li, Shugeng Gao, Jié He

2023Journal of Thoracic Oncology54 citationsDOIOpen Access PDF

Topics & Concepts

MedicineApatinibOncologyInternal medicineBiomarkerClinical trialPhases of clinical researchChemotherapyOverall survivalChemistryBiochemistryCancer Immunotherapy and BiomarkersColorectal and Anal CarcinomasNonmelanoma Skin Cancer Studies
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial | Litcius